Literature DB >> 22313953

Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.

Olawale Ajose1, Siddharth Mookerjee, Edward J Mills, Andrew Boulle, Nathan Ford.   

Abstract

BACKGROUND: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings.
METHODS: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form.
RESULTS: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points.
CONCLUSION: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313953     DOI: 10.1097/QAD.0b013e328351f5b2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  87 in total

1.  Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.

Authors:  Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange
Journal:  AIDS       Date:  2019-09-01       Impact factor: 4.177

Review 2.  Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Authors:  Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

3.  HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.

Authors:  Rami Kantor; Allison DeLong; Leeann Schreier; Marissa Reitsma; Emanuel Kemboi; Millicent Orido; Salome Obonge; Robert Boinett; Mary Rono; Wilfred Emonyi; Katie Brooks; Mia Coetzer; Nathan Buziba; Joseph Hogan; Lameck Diero
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

4.  Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.

Authors:  Julia K Rohr; Prudence Ive; Charles Robert Horsburgh; Rebecca Berhanu; Christopher J Hoffmann; Robin Wood; Andrew Boulle; Janet Giddy; Hans Prozesky; Michael Vinikoor; Mwanza Wa Mwanza; Gilles Wandeler; Mary-Ann Davies; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

5.  Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia.

Authors:  Linda Aurpibul; Sirinya Teerananchai; Wasana Prasitsuebsai; Tavitiya Sudjaritruk; Pope Kosalaraksa; Nia Kurniati; Khanh Huu Truong; Viet Chau Do; Lam Van Nguyen; Kulkanya Chokephaibulkit; Thida Singtoroj; Stephen J Kerr
Journal:  Ther Drug Monit       Date:  2016-12       Impact factor: 3.681

6.  The interaction between equipoise and logistics in clinical trials: A case study.

Authors:  Meredith G Warshaw; Vincent J Carey; Elizabeth J McFarland; Liza Dawson; Elaine Abrams; Ann Melvin; Lee Fairlie; Hans Spiegel; Jonathan Jay; Allison L Agwu
Journal:  Clin Trials       Date:  2017-01-31       Impact factor: 2.486

7.  Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.

Authors:  Victoria Johnston; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

8.  Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.

Authors:  Denise Evans; Sara Dahlberg; Rebecca Berhanu; Tembeka Sineke; Caroline Govathson; Ingrid Jonker; Elisabet Lönnermark; Matthew P Fox
Journal:  AIDS Care       Date:  2018-02-21

9.  A Systematic Review on Promoting Adherence to Antiretroviral Therapy in HIV-infected Patients Using Mobile Phone Technology.

Authors:  Yuri Quintana; Eduardo A Gonzalez Martorell; Darren Fahy; Charles Safran
Journal:  Appl Clin Inform       Date:  2018-06-20       Impact factor: 2.342

10.  Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy.

Authors:  Richard Court; Michelle Gordon; Karen Cohen; Annemie Stewart; Bernadett Gosnell; Lubbe Wiesner; Gary Maartens
Journal:  Int J Antimicrob Agents       Date:  2016-06-09       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.